Rituximab: clinical development and future directions

被引:24
作者
Cheson, BD [1 ]
机构
[1] NCI, Bethesda, MD 20892 USA
关键词
antibody; CD20; CLL lymphoma; monoclonal; rituximab;
D O I
10.1517/14712598.2.1.97
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The availability of effective monoclonal antibodies (mAbs) has revolutionised the management of patients with B-cell malignancies. The most widely studied of these agents is rituximab (Rituxan(TM), IDEC Pharmaceuticals, San Diego, CA), a chimeric anti-CD20 antibody. Using the standard 4-weekly administration schedule, rituximab induces responses in almost half of patients with relapsed follicular/low-grade (F/LG) non-Hodgkin's lymphoma (NHL) with complete remissions in 6%. Lower response rates (RRs) have been noted in chronic lymphocytic leukaemia (CLL) using the standard dose and schedule. The drug has been well tolerated in most patients with common adverse events including mild to moderate fevers and chills and rare occurrences of a serious syndrome related to cytokine release and rapid tumour clearance. This antibody is also active against aggressive NHL, mantle cell NHL, post-transplant lymphoproliferative disorder (PTLD), lymphoplasmacytic NHL and hairy cell leukaemia and is also being evaluated in autoimmune disorders. Combinations of rituximab with chemotherapy regimens such as CHOP (cyclophosphamide, adriamycin, vincristine, predinisone) may alter the therapeutic paradigm for these diseases. The future promise of this antibody is a foundation on which to develop new strategies to increase the cure of patients with lymphoid malignancies.
引用
收藏
页码:97 / 110
页数:14
相关论文
共 108 条
[91]  
Thomas DA, 1999, BLOOD, V94, p705A
[92]  
Treon SP, 1999, BLOOD, V94, p312A
[93]   Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies [J].
Treon, SP ;
Mitsiades, C ;
Mitsiades, N ;
Young, G ;
Doss, D ;
Schlossman, R ;
Anderson, KC .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (03) :263-271
[94]  
TREON SP, 2000, P AN M AM SOC CLIN, V19, pA6
[95]  
TREON SP, 1999, ANN ONCOL S, V10, P34
[96]  
van der Kolk LE, 2000, BLOOD, V96, p732A
[97]  
Venugopal P, 1998, BLOOD, V92, p247A
[98]  
Visconti JL, 1999, BLOOD, V94, p270B
[99]   Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma [J].
Vose, JM ;
Link, BK ;
Grossbard, ML ;
Czuczman, M ;
Grillo-Lopez, A ;
Gilman, P ;
Lowe, A ;
Kunkel, LA ;
Fisher, RI .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :389-397
[100]   Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma [J].
Weng, WK ;
Levy, R .
BLOOD, 2001, 98 (05) :1352-1357